Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? - Wikidata - awgldk - TriplyDB

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

http://www.wikidata.org/entity/Q27022117

about

Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Rheumatology around the world: perspectives from Australia and New Zealand.B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.

P2860

Q37381549-2A643FE7-B618-46EC-B9C4-8D5F0BCFED95 Q42322540-F44D9160-3E7A-4917-8EE3-4DD43BE7A716 Q42771422-B0DA0FB9-DFE1-4AF4-9AAC-443FC54ECE0D Q47107441-59C7C95E-0A93-4C83-A5E4-DB4198EF189B Q47839424-8B8F6E78-D29F-4B87-89CA-02B45DEF2A9D Q51295804-D7584A8B-7C5B-436A-BE58-01772B4EEA31 Q53352678-21D20680-E3C4-4611-A39A-6CB40055B388

P2860

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

http://www.wikidata.org/entity/Q27022117

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@ast

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@en

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@nl

type

label

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@ast

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@en

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@nl

prefLabel

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@ast

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@en

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@nl

P1433

Q27022117-3E67091F-6C4C-455B-9C1C-CA557E9D3E53

P1476

Q27022117-AAD9673E-6190-457B-B3EE-3624EB8DDCBB

P2093

Q27022117-5ACA1C99-D0BF-4453-96C4-4F527AF07D7B

Q27022117-81DC8A77-26BE-4EA7-BB6D-8CCF4DEC5746

P2860

Q27022117-052D9B48-FBF7-4AC4-A337-3EBDF79666AE

Q27022117-07EEFB5E-82BB-402B-BA7A-FAB8B6364CEB

Q27022117-0926FAF1-09BF-4629-B9F1-A80024E37CB6

Q27022117-0938ABBD-7BFF-455F-AB4D-52032444CAD5

Q27022117-0994DD52-BEDB-4518-A603-C56E9D68DAC8

Q27022117-0F87F7AC-2015-48BD-AC0B-8DCDBACD2D4C

Q27022117-11E42B76-507C-467A-B9CE-0760CBBDDCF0

Q27022117-15C5793B-192B-4981-8D4E-E5768F0D8F8A

Q27022117-208BFA02-23AF-4800-8893-0505B52AD05C

Q27022117-26333676-E60B-4BE6-8AD6-EF817E3FDACC

P304

Q27022117-C6B57C34-171C-447E-8B7B-76714E32D270

P31

Q27022117-EC3F5D11-11BA-4B3B-8F16-5576D8055E8B

P3181

Q27022117-DCA8B0AE-2099-42E1-AF2F-5EADD92C6F3E

P356

Q27022117-1D5AA834-D6D2-4F90-8D18-4EAE577D8F34

P407

Q27022117-0411D599-A41B-46C9-B045-ADBC66A8FC8D

P433

Q27022117-DF758A66-B3B0-409C-BCD5-B56D78E53CB8

P478

Q27022117-3581BCAC-046C-4C62-8DAF-055C5A97FC87

P577

Q27022117-802CEA8E-FBBE-455F-B73E-BB824405F703

P698

Q27022117-E2C82CAC-9EC9-4118-ABDE-D4AACFF44F53

P3181

P356

P1433

P1476

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

@en

P2093

F. M. McQueen

http://www.w3.org/2001/XMLSchema#string

K. Solanki

http://www.w3.org/2001/XMLSchema#string

P2860

Predominant autoantibody production by early human B cell precursors

Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts.

B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin

Data sources for improving estimates of the global burden of injuries: call for contributors.

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis.

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort

Cyclophosphamide versus placebo in scleroderma lung disease.

P304

757-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1454136

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/RHEUMATOLOGY/KEU463

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25573841

http://www.w3.org/2001/XMLSchema#string